ClinicalTrials.gg
CompletedNCT05949385Updated Nov 5, 2024

A Study to Assess the Effect of Itraconazole Capsules on the Pharmacokinetics of ZX-7101A Tablets in Healthy Adult Subjects in China

A Phase 1 interventional study of ZX-7101A in Pharmacokinetics, sponsored by Nanjing Zenshine Pharmaceuticals. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-05.

Sponsored by Nanjing Zenshine Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The primary objective of the study is to evaluate the effect of Itraconazole on pharmacokinetics of ZX-7101 in healthy Chinese adult subjects after oral administration of ZX-7101A tablets.

The secondary objective of the study is to evaluate the safety and tolerability of single dose of ZX-7101A orally in healthy subjects.

Evaluate the effect of Itraconazole on pharmacokinetics of pre-drug ZX-7101A in healthy Chinese adult subjects after oral administration of ZX-7101A tablets.

Read the detailed description

ZX-7101A tablets 40 mg once on Day 1 and Day 31, Itraconazole 200 mg once daily (QD) from Study Day 26 - 50

02

Conditions studied

  • Pharmacokinetics

Keywords

  • DDI
03

In context

Lead sponsor

Nanjing Zenshine Pharmaceuticals is the lead sponsor of 16 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female subjects between the ages of 18 and 45 years (including the threshold value, based on the date of signing ICF).
  • Weight: Male weight ≥50 kg, female weight ≥45 kg, between 19.0 and 28.0 kg/m2 (including cut-off value), BMI= weight (kg)/height 2 (m2).
  • The investigator judged the subjects to be in good overall health based on their medical history, physical examination, vital signs, 12-lead , laboratory tests (routine blood work, urine work, blood biochemistry, coagulation function), viral serology, and chest X-ray results (normal or abnormal test results have no clinical significance).
  • Fertile female subjects or male subjects who voluntarily signed ICF should be no fertile, sperm/egg donation for 6 months (female) or 90 days (male) from the beginning to the last dose, and voluntary use highly effective (including partner) (non-drug contraception is required during the trial).
  • Fully understand the trial content and possible adverse reactions, have the ability to communicate with researchers normally, while complying with study requirements, follow protocol procedures and restrictions, and be able to visit on time.

Exclusion criteria

Exclusion Criteria:

  • Subjects with a prior or present history of clinically abnormal metabolic, liver, kidney, hematological, pulmonary, cardiovascular, gastrointestinal, urinary, endocrine, neurological, or psychiatric disease who were judged by the investigator to be unsuitable for participation in this study.
  • Subjects with digestive tract disease or any condition that may affect drug absorption, such as a history of liver and gallbladder disease, gastrointestinal disease, gastrointestinal surgery (except appendectomy) or a history of chronic pancreatitis, idiopathic acute pancreatitis, or habitual diarrhea.
  • Allergic constitutions (such as allergies to two or more drugs, foods, and pollen), or determined by the investigator, may be allergic to the product or any component of the investigational product.
  • Acute respiratory infections within 2 weeks before screening; Or have a history of fungal infection.
  • For patients with abnormal vital signs (blood pressure, pulse rate, ear temperature) and results, the abnormal values of each vital sign are:Body temperature (ear temperature) >37.5 ℃; Systolic blood pressure (recumbent) \<90 mmHg or ≥140 mmHg; Diastolic blood pressure (lying) \<50 mmHg or ≥90 mmHg; Pulse rate (lying position) \<50 beats/min or >100 beats/min.
  • interval > 450ms or \< 300 ms (Fridericia's correction), or QRS>120ms. Abnormal liver function: alanyl aminotransferase () or aspartate aminotransferase (AST) higher than the or serum total (TBIL) greater than 1.5 times the upper limit of normal, who judged clinical significance by investigators.
  • Subjects estimate \<90 mL/min/1.73 m2.
  • Subjects virus serological test ( virus surface antigen, virus antibody, antibody, treponema pallidum specific antibody TPPA) positive results.
  • Subjects with a history of drug abuse (morphine, dimethylene dioxyamphetamine, methamphetamine, THC, ketamine, cocaine) or who screened positive for drug abuse.
  • Women who are pregnant or breastfeeding, or who test positive for blood pregnancy.
  • Subjects who have used any P-gp or CYP inducer or inhibitor within 30 days before screening, or any prescription or Chinese herbal medicine within 4 weeks before the start of the trial, or over-the-counter or health care products (including polyvalent cations and metal supplements, etc.) within 2 weeks before the start of the trial; It should have a longer time interval if the elimination half-life is longer-at least 5 elimination half-lives for the drug.
  • Subjects who consumed more than 14 units of alcohol per week in the 6 months prior before screening (1 unit of alcohol =360mL beer or 45mL spirits with 40% alcohol or 150mL wine) or had a positive alcohol breath test or could not abstain during the trial.
  • Subjects who smoked more than 5 cigarettes per day in the 3 months prior before screening or habitually used nicotine-containing products or could not give up during the trial.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    ZX-7101A and Itraconazole

    D1 and D31 Take ZX-7101A tablet 40mg (1 tablet, 40mg/ tablet),oral,fasting; D26-D50 Itraconazole capsule 200mg(2 capsules, 100mg/ capsule) ,oral in 30min after breakfast.

    Drug: ZX-7101A

Interventions

  • Single dose of oral administration of ZX-7101A and Multiple dose of oral of Itraconazole Capsules

    Also known as: Itraconazole

06

What researchers measure

Primary outcomes

  1. PK parameters of active metabolite ZX-7101after a single oral ZX-7101A tablet and combined with multiple oral itraconazole capsules in healthy Chinese adult subjects

    Cmax

    Time frame: Day1-Day20, Day31-Day50

  2. PK parameters of active metabolite ZX-7101after a single oral ZX-7101A tablet and combined with multiple oral itraconazole capsules in healthy Chinese adult subjects

    AUC0-t

    Time frame: Day1-Day20, Day31-Day50

  3. PK parameters of active metabolite ZX-7101after a single oral ZX-7101A tablet and combined with multiple oral itraconazole capsules in healthy Chinese adult subjects

    AUC0-inf

    Time frame: Day1-Day20, Day31-Day50

Secondary outcomes

  1. Rate of AE

    Rate of TEAE

    Time frame: Day1-Day20, Day31-Day50

  2. PK parameters of prodrug ZX-7101A

    Cmax

    Time frame: Day1-Day20, Day31-Day50

  3. PK parameters of prodrug ZX-7101A

    AUC0-t

    Time frame: Day1-Day20, Day31-Day50

  4. PK parameters of prodrug ZX-7101A

    AUC0-inf

    Time frame: Day1-Day20, Day31-Day50

  5. PK parameters of ZX-7101

    Tmax

    Time frame: Day1-Day20, Day31-Day50

  6. PK parameters of ZX-7101

    CL/F

    Time frame: Day1-Day20, Day31-Day50

07

Study locations

1 site
  • Huashan Hospital affiliated to Fudan University
    Shanghai, Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Sep 2023, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2023
First posted
Jul 18, 2023
StartActual
Jul 2, 2023
Primary completionActual
Sep 23, 2023
CompletionActual
Jan 11, 2024
Last update
Nov 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05949385
Lead sponsor
Nanjing Zenshine Pharmaceuticals
Responsible party
Sponsor
First posted
Jul 18, 2023
Start date
Jul 2, 2023
Primary completion
Sep 23, 2023
Completion
Jan 11, 2024
Last update
Nov 5, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sebaloxavir marboxil

Start the discussion